RCHAD is a fully reporting company that files audited financials with the SEC that has received FDA Approval to start Phase I/II (1/2) for treating Acute Myelocytic Leukemia (AML) and Hodgkin's Lymphoma (HL) with its principal doctor, Dr. Tontanai Numbenjapon, who will commence Clinical Trials in Phramongkutklao Hospital in Thailand per the recent news indicated below:
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.